Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,214,965 papers from all fields of science
Search
Sign In
Create Free Account
ANTI-INHIBITOR COAGULANT COMPLEX
Known as:
coagulation factor IX, II, VII and X in combination
, Factor VIII bypassing fraction
, Factor VIII inhibitor bypassing activity
Expand
A sterile, freeze dried fraction of human plasma containing factor VIII coagulant antigen and both the inactive and active forms of coagulation…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
10 relations
ANTI-INHIBITOR COAGULANT COMPLEX 1 UNT Injection
Drug Allergy
Enzyme Activators [MoA]
Reversed Anticoagulation Activity [PE]
Expand
Narrower (2)
ANTI-INHIBITOR COAGULANT COMPLEX 1 UNT Injection [Feiba]
Feiba
Broader (2)
Blood Coagulation Factor
Coagulants
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents.
Toshio Fukuda
,
Y. Honda
,
Chikako Kamisato
,
Y. Morishima
,
T. Shibano
Thrombosis and Haemostasis
2011
Corpus ID: 5426929
Edoxaban, an oral, direct factor Xa inhibitor, has a similar or low incidence of bleeding events compared with other…
Expand
Review
2011
Review
2011
Why caretakers bypass Primary Health Care facilities for child care - a case from rural Tanzania
C. Kahabuka
,
G. Kvåle
,
K. Moland
,
S. Hinderaker
BMC Health Services Research
2011
Corpus ID: 6686826
BackgroundResearch on health care utilization in low income countries suggests that patients frequently bypass PHC facilities in…
Expand
Highly Cited
2007
Highly Cited
2007
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.
J. Astermark
,
S. Donfield
,
+4 authors
E. Berntorp
Blood
2007
Corpus ID: 24392650
The development of inhibitory antibodies to factor VIII is a serious complication of hemophilia. FEIBA (factor VIII inhibitor…
Expand
Highly Cited
2005
Highly Cited
2005
Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision
Y. Dargaud
,
A. Lienhart
,
+5 authors
C. Négrier
Haemophilia
2005
Corpus ID: 25885178
Summary. In haemophilia patients with inhibitor, elective orthopaedic surgery is usually performed under recombinant activated…
Expand
Review
2004
Review
2004
Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors
T. Abshire
,
G. Kenet
Journal of Thrombosis and Haemostasis
2004
Corpus ID: 35510450
Summary. Recombinant factor (rF)VIIa has been available to clinicians since 1996 and has an excellent safety record after almost…
Expand
Highly Cited
2004
Highly Cited
2004
Treatment of acquired haemophilia with factor eight inhibitor bypassing activity
S. Sallah
Haemophilia
2004
Corpus ID: 816033
Summary. Haemorrhagic manifestations in patients with acquired haemophilia can be fatal if not recognized and treated…
Expand
Highly Cited
2004
Highly Cited
2004
Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity
L. Aledort
Journal of Thrombosis and Haemostasis
2004
Corpus ID: 34862036
Summary. Thrombosis is a rare but well‐recognized potential complication of Factor VIII Inhibitor Bypass Activity (FEIBA…
Expand
Highly Cited
2003
Highly Cited
2003
Factor VIII Inhibitor-Bypassing Agents Act by Inducing Thrombin Generation and Can Be Monitored by a Thrombin Generation Assay
P. Turecek
,
K. Váradi
,
+7 authors
H. Schwarz
Pathophysiology of Haemostasis and Thrombosis
2003
Corpus ID: 31434252
Factor VIII (FVIII)-bypassing agents have complex modes of action but all control bleeding in inhibitor patients by triggering…
Expand
Highly Cited
2001
Highly Cited
2001
Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
M. Elg
,
S. Carlsson
,
D. Gustafsson
Thrombosis Research
2001
Corpus ID: 24438828
Highly Cited
1997
Highly Cited
1997
Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
C. Négrier
,
J. Goudemand
,
Y. Sultan
,
M. Bertrand
,
C. Rothschild
,
P. Lauroua
Thrombosis and Haemostasis
1997
Corpus ID: 2592114
Factor VIII or factor IX replacement is frequently impossible in inhibitor-developing hemophiliacs, because of the level of the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE